Category: piperazines

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.

5317-33-9, To a solution of 3-N-(4-methylpiperazinyl)propan-1-ol (8.81 mmol, 1.39 g) in THF (40 ML) under N2 was added sodium metal (13.2 mmol, 0.30 g). The resulting suspension was stirred at 20 C. for 2 hours and then cannulated into a solution of 4-[(3-bromophenyl)amino]-7-fluoro-6-nitroquinazoline [J Med Chem, 1996(39):918] (0.80 g, 2.20 mmol) in THF (30 mL) under N2. Identical reaction procedure and workup as in the previous example gave, after chromatography on silica gel eluting with MeOH/CH2Cl2/EtOAc (1:9:10) to MeOH/CH2Cl2/EtOAc (2:3:5), 4-[(3-bromophenyl)amino)-7-[3-N-(4-methylpiperazinyl)propyloxy]-6-nitroquinazoline (0.36 g, 33%) as a yellow powder, mp (trihydrochloride salt) (MeOH/Et2O) 233 C. (dec). 1H NMR (free base, (CD3)2SO]: delta 10.12 (s, 1H, NH), 9.24 (s, 1H, H5), 8.69 (s, 1H, H2), 8.19 (br s, 1H, H-2′), 7.88 (br d, J=7.8 Hz, 1H, H-6′), 7.47 (s, 1H, H8), 7.38 (t, J=7.8 Hz, 1H, H-5′), 7.34 (dt, Jd=8.0, Jt=1.3 Hz, 1H, H-4′), 4.33 (t, J=6.1 Hz, 2H, CH2CH2CH2O), 2.45 (t, J=7.0 Hz, 2H, NCH2CH2CH2), 2.42-2.29 (br s, 8H, piperazinyl methylene), 2.15 (s, 3H, CH3N), 1.92 (quintet, J=6.7 Hz, 2H, CH2CH2CH2). Analysis calculated for C22H25BrN6O3.3HCl.H2O requires: C, 42.0; H, 4.8; N, 13.4; Cl, 16.9%. Found: C, 42.1; H, 4.5; N, 13.3; Cl, 16.9%.

5317-33-9 3-(4-Methylpiperazin-1-yl)propan-1-ol 79208, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Warner-Lambert Company; US6344459; (2002); B1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

197638-83-8, 1-Boc-4-(4-Formylphenyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 1 te/t-Butyl-4-(4-(6-bromo-7-(4-(cyclobutylmethyl)piperazin-1-yl)-3H-imidazo[4,5- b]pyridin-2-yl)phenyl)piperazine-1-carboxylateTo a mixture of 5-bromo-4-(4-(cyclobutylmethyl)piperazin-1-yl)-3-nitropyridin-2-amine (prepared as described in example 149 of PCT/GB2006/004854; 0.12 g, 0.32 mmol, 1eq) in EtOH (5.6 ml_) and DMF (0.74 ml_), tert-butyl 4-(4-formylphenyl)piperazine-1- carboxylate (0.102 g, 0.35 mmol, 1.1 eq) was added followed by a freshly prepared aqueous solution of Na2S2O4 (1 M; 0.96 mL, 0.96 mmol). The reaction mixture was heated at 85 0C for 24 h, then allowed to cool to room temperature and diluted with DCM and a few drops of aqueous NH3 until complete dissolution was observed. This solution was deposited on two preparative silica TLC plates and eluted with DCM/MeOH (v/v 94:6) to give the title compound as an off-white solid (0.043 g, 22%); 1H-NMR (500Mz, DMSO-c/6): delta 1.43 (s, 9H, C(CH3)3), 1.60-1.75 (m, 2H), 1.76- 1.94 (m, 2H), 2.00-2.11 (m, 2H), 2.35-2.48 (brs, 2H), 2.50-2.65 (m, 4H), 3.43-3.52 (m, 4H), 3.55-3.69 (brs, 4H), 7.07 (d, J = 9.0 Hz, 2H, ArH, C6H4), 8.04 (d, J = 8.5 Hz, 2H, ArH, C6H4), 8.17 (s, 1H, imidazo[4,5-b]pyridine 5-H)1 13.22 (br s, 1 H1 imidazo[4,5-b]pyridine N-H), two signals (one from the cyclobutyl ring and that from one of the two piperazinyl ring were hidden under solvents’ signals; LC (Method B) – MS (ESI, m/z) 3.86 min – 610/612 [(M+H)+, Br isotopic pattern]. ESI-HRMS: Found: 610.2504, calculated for C30H4iN7O2Br (M+H)+: 610.2499., 197638-83-8

197638-83-8 1-Boc-4-(4-Formylphenyl)piperazine 2795509, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; CHROMA THERAPEUTICS LTD.; WO2009/1021; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

5464-12-0, 1-(2-Hydroxyethyl)-4-methylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

c. 5-tert-Butyl-2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-ylamine (Intermediate 13c) To a solution of Intermediate 13b (1.15 g, 5.0 mmol), 2-(4-methyl-piperazin-1-yl)-ethanol (864 mg, 6.0 mmol), and triphenylphosphine (2.62 g, 10.0 mmol) in THF (10 mL), was added diisopropyl azodicarboxylate (2.0 g, 10.0 mmol) dropwise and stirred for 75 min. The mixture was diluted with diethyl ether (50 mL) and extracted with 10percent aqueous citric acid soln (2*). The combined aqueous layers were basified with solid potassium carbonate until pH=9. The aqueous layer was then extracted with ethyl acetate (3*). The combined ethyl acetate layers were washed with brine, dried (NaSO4) and evaporated in vacuo. Purification by FCC using 0-12percent [9:1 MeOH/880 ammonia] in DCM. The resulting product was crystallised (diethyl ether) to give the title compound (270 mg, 0.756 mmol, 15percent). LCMS (Method 1): Rt 2.31, 1.72 min, m/z 358/359 [MH+].

5464-12-0, Big data shows that 5464-12-0 is playing an increasingly important role.

Reference£º
Patent; Chiesi Farmaceutici S.p.A.; Van Niel, Monique Bodil; Ray, Nicholas Charles; Cridland, Andrew Peter; Hurley, Christopher; Alcaraz, Lilian; Panchal, Terry Aaron; Jennings, Andrew Stephen Robert; Armani, Elisabetta; US2013/150361; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.59702-07-7,1-Methylpiperazin-2-one,as a common compound, the synthetic route is as follows.

59702-07-7, To a vial were added methyl 6-bromoisoquinoline-3-carboxylate (83 mg, 0.31 mmol), 1- methylpiperazin-2-one (85 mg, 0.74 mmol), potassium phosphate, tribasic (175 mg, 0.81 mmol) and dioxane (2.5mL). The mixture was degassed by sparging with argon, RuPhos palladacycle Gen 4 pre-catalyst (22 mg, 8 mol%) was added and the vial was sealed and stirred at 100 C overnight. The reaction mixture was filtered, collected solids washed with EtOAc and purified on Si02 (0-10% methanol/dichloromethane) to give titled compound titled compound (20 mg 16%) as a yellow solid.

As the paragraph descriping shows that 59702-07-7 is playing an increasingly important role.

Reference£º
Patent; NURIX THERAPEUTICS, INC.; BARSANTI, Paul A.; BENCE, Neil F.; GOSLING, Jennifa; SAHA, Anjanabha; TAHERBHOY, Asad M.; ZAPF, Christoph W.; BOYLE, Kathleen; CARDOZO, Mario; MIHALIC, Jeffrey; LAWRENZ, Morgan; GALLOP, Mark; BRUFFEY, Jilliane; CUMMINS, Thomas; ROBBINS, Daniel; TANAKA, Hiroko; WANG, Chenbo; COHEN, Frederick; PALMER, Wylie; SANDS, Arthur T.; SHUNATONA, Hunter; (968 pag.)WO2019/148005; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

76003-29-7, 1-Boc-3-Oxopiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

76003-29-7, To a solution of 1,1-dimethylethyl 3-oxo-1-piperazinecarboxylate (500 mg, 2.497 mmol) in N,N-dimethylformamide (DMF) (8 mL) at room temperature under nitrogen was added sodium hydride (60% w/w in mineral oil, 120 mg, 3.00 mmol) and the resulting suspension was stirred at this temperature for 30 min. 1-Bromo-4-(bromomethyl)benzene (749 mg, 3.00 mmol) in DMF (5 mL) was then added via syringe. The resulting mixture was stirred at room temperature for 1.5 h then partitioned between AcOEt and water. The layers were separated and the aqueous phase was extracted three times with AcOEt. The combined organic phases were washed three times with brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by SP4 using a 25 G silica cartridge (gradient: 13 to 63% AcOEt in Hexanes) gave 1,1-dimethylethyl 4-[(4-bromophenyl)methyl]-3-oxo-1-piperazinecarboxylate (763 mg, 2.066 mmol, 83% yield) as an oil which solidified to a white solid over 16 h.LCMS (method A): Retention time 1.14 min, [M+H]+=370.95 (1 Br)

As the paragraph descriping shows that 76003-29-7 is playing an increasingly important role.

Reference£º
Patent; Demont, Emmanuel Hubert; Garton, Neil Stuart; Gosmini, Romain Luc Marie; Hayhow, Thomas George Christopher; Seal, Jonathan; Wilson, David Matthew; Woodrow, Michael David; US2012/208798; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

314741-39-4, (S)-1-tert-Butyl 3-methyl piperazine-1,3-dicarboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A 50 L glass-lined reactor was charged with the above solution of ethyl 3-isocyanato-2,2- dimethyl-propanoate (Example 1) in DCM . To the solution, cooled to 5-10 C, was added 01-tert-butyl 03-methyl (3S)-piperazine-1,3-dicarboxylate (2.64 kg, 10.81 mol, Compound IV) in portions below 10 C. The reaction mixture was stirred for 2 hours at 25 C. The solvent was removed at 40 C/0.O7MPa to give the crude Example 2 (4.9 kg, purity: 94.98 %) which was used directly for the next step. Analytically pure Example 2 was obtained as an oil by flash chromatography. ?H NMR (400 MHz, CDC13) (55.45-5.48 (m, 1H), 4.85 (s, br, 1H), 4.54 (d, J=13.6, 1H), 4.12 (q, J= 7.6, 2H), 3.69 (s, 3H), 3.30-3.38 (m, 4H), 3.06-3.09 (m, 1H), 2.87 (s, br,1H), 1.41 (s, 9H), 1.24 (t, J= 7.6, 3H), 1.16 (s, 6H); MS mle = 416.1 [M+H] ., 314741-39-4

The synthetic route of 314741-39-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; CHEN, Junli; (58 pag.)WO2017/140750; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.197638-83-8,1-Boc-4-(4-Formylphenyl)piperazine,as a common compound, the synthetic route is as follows.

A solution of 4-(4-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (1.3 g, 4.47 mmol) in THF (50 mL) was mixed with LAH (0.7 g, 17.87 mmol) and stirred at reflux for 14 h. The reaction was quenched at room temperature by adding KOH aqueous (14 N, 20 mL). The supernatant was decanted and combined with DCM washings, then diluted with water (50 mL). The mixture was extracted with DCM (3¡Á50 mL) followed by concentration using a rotary evaporator to give [4-(4-methyl-piperazin-1-yl)-phenyl]-methanol (0.82 g, 89%). To a solution of DMSO (0.56 mL, 7.96 mmol) in DCM (50 mL) at -78 C. was added oxalyl chloride (0.7 mL, 7.96 mmol) and the resulting mixture was stirred at -78 C. for 0.5 h. A solution of [4-(4-methyl-piperazin-1-yl)-phenyl]-methanol (0.82 g, 3.98 mmol) in DCM (20 mL) was slowly added. The reaction was stirred at -78 C. for 1.5 h. Triethylamine (1.7 mL, 11.94 mmol) was added and the reaction was allowed to gradually warm up to room temperature. After stirring for 4 h the reaction was quenched by adding sodium bicarbonate aqueous (1 N, 50 mL). The mixture was extracted with DCM (3¡Á50 mL) followed by concentration to afford a residue, which was further purified by column chromatography to yield 4-(4-methyl-piperazin-1-yl)-benzaldehyde (0.5 g, 61%).5,7-Dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one was synthesized from 2-amino-4,6-dimethoxybenzamide and 4-(4-methyl-piperazin-1-yl)-benzaldehyde, using the method described for 5,7-dimethoxy-2-(pyridin-2-yl)quinazolin-4(3H)-one. 5,7-Dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one (120 mg, 41%) was converted to the corresponding hydrochloride (a yellow solid). Selected data: MS (m/z): 381.11; MP 252.4-254.2 C. (di-hydrochloride)., 197638-83-8

197638-83-8 1-Boc-4-(4-Formylphenyl)piperazine 2795509, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Wong, Norman C.W.; Tucker, Joseph E.L.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; McCaffrey, David; US2008/188467; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.342405-34-9,4-(4-Methylpiperazino)benzyl Alcohol,as a common compound, the synthetic route is as follows.

A solution of 4-(4-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (1.3 g, 4.47 mmol) in THF (50 mL) was mixed with LAH (0.7 g, 17.87 mmol) and stirred at reflux for 14 h. The reaction was quenched at room temperature by adding KOH aqueous (14 N, 20 mL). The supernatant was decanted and combined with DCM washings, then diluted with water (50 mL). The mixture was extracted with DCM (3¡Á50 mL) followed by concentration using a rotary evaporator to give [4-(4-methyl-piperazin-1-yl)-phenyl]-methanol (0.82 g, 89%). To a solution of DMSO (0.56 mL, 7.96 mmol) in DCM (50 mL) at -78 C. was added oxalyl chloride (0.7 mL, 7.96 mmol) and the resulting mixture was stirred at -78 C. for 0.5 h. A solution of [4-(4-methyl-piperazin-1-yl)-phenyl]-methanol (0.82 g, 3.98 mmol) in DCM (20 mL) was slowly added. The reaction was stirred at -78 C. for 1.5 h. Triethylamine (1.7 mL, 11.94 mmol) was added and the reaction was allowed to gradually warm up to room temperature. After stirring for 4 h the reaction was quenched by adding sodium bicarbonate aqueous (1 N, 50 mL). The mixture was extracted with DCM (3¡Á50 mL) followed by concentration to afford a residue, which was further purified by column chromatography to yield 4-(4-methyl-piperazin-1-yl)-benzaldehyde (0.5 g, 61%).5,7-Dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one was synthesized from 2-amino-4,6-dimethoxybenzamide and 4-(4-methyl-piperazin-1-yl)-benzaldehyde, using the method described for 5,7-dimethoxy-2-(pyridin-2-yl)quinazolin-4(3H)-one. 5,7-Dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one (120 mg, 41%) was converted to the corresponding hydrochloride (a yellow solid). Selected data: MS (m/z): 381.11; MP 252.4-254.2 C. (di-hydrochloride).

342405-34-9, The synthetic route of 342405-34-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Wong, Norman C.W.; Tucker, Joseph E.L.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; McCaffrey, David; US2008/188467; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1235865-77-6,2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid,as a common compound, the synthetic route is as follows.

(1058) To a solution of Compound 3J (617 mg) and Compound 340A (386 mg) in dichloromethane (10 ml) was added 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (288 mg) and 4-(dimethylamino)pyridine (183 mg). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 ml) and washed with aqueous NaHCO3, water, brine and dried over Na2SO4. Filtration and evaporation of the solvent gave the title compound.

1235865-77-6, The synthetic route of 1235865-77-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AbbVie Inc.; Catron, Nathaniel; Lindley, David; Miller, Jonathan M.; Schmitt, Eric A.; Tong, Ping; US10213433; (2019); B2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

694499-26-8, 4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

694499-26-8, General procedure: To a solution of 3-iodo-4-methylbenzoyl chloride obtained above in dry DCM (10mL) at 0C was added Et3N (0.28mL, 2.0mmol) and 4-((4-methylpiperazin-1-yl) methyl)-3-(trifluoromethyl) aniline (328mg, 1.2mmol). The mixture was stirred at room temperature for 5h, and then the solvent was removed under reduced pressure. The residue was purified by using column chromatography to afford the corresponding product 6-1 (439mg, 2 steps yield: 85%).

As the paragraph descriping shows that 694499-26-8 is playing an increasingly important role.

Reference£º
Article; Liu, Yang; Peng, Xia; Guan, Xiaocong; Lu, Dong; Xi, Yong; Jin, Shiyu; Chen, Hui; Zeng, Limin; Ai, Jing; Geng, Meiyu; Hu, Youhong; European Journal of Medicinal Chemistry; vol. 126; (2017); p. 122 – 132;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics